Comparison · NCT00294047-3a1b3479
Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Medically Significant Conditions (MAEs).
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Medically Significant Conditions (MAEs). Trial comparisons, record NCT00294047-3a1b3479. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00294047-3a1b3479
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.407 | 0.389 | 0.425 | wilson | |
| Risk in group 2 | 0.397 | 0.379 | 0.415 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00946 | -0.0159 | 0.0348 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.961 | 1.09 | log | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.936 | 1.16 | log | |
| Number needed to treat, for one more participant with the outcome on Cervarix Group than on Aluminium Hydroxide Group | 106 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cervarix Group | Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule. | 1,170 | 2,877 | OG000 |
| Group 2 | Aluminium Hydroxide Group | Subjects received 3 doses of Aluminium Hydroxide \[Al(OH)3\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule. | 1,140 | 2,870 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Reporting Medically Significant Conditions (MAEs).
- Description
Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.
- Time frame
- Up to Month 48
- Population
- The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
- NCT number
- NCT00294047
- Phases
- PHASE3
- Conditions
- Infections, Papillomavirus, Papillomavirus Vaccines
- Interventions
- Cervarix, Placebo control
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2012-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00294047?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00294047-3a1b3479